buformin has been researched along with Adenocarcinoma, Basal Cell in 1 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anisimov, VN | 1 |
| Ostroumova, MN | 1 |
| Dil'man, VM | 1 |
1 other study available for buformin and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
[Inhibition of the blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female rats by buformin, diphenin, a polypeptide pineal extract and L-DOPA].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Adenofibroma; Animals; Antineoplastic Agents; Benz | 1980 |